Fate Therapeutics Strikes Multi-Billion Dollar Cell Therapy Deal with Janssen – BioSpace

Shares of Fate Therapeutics were up more than 21% in premarket trading after the company announced a multi-billion dollar deal with Janssen Biotech to develop cell therapies for the treatment of cancer.

The partnership will leverage San Diego-based Fate Therapeutics induced pluripotent stem cell (iPSC) product platform and Janssens proprietary tumor-targeting antigen binders to create novel CAR NK and CAR T-Cell product candidates that will be developed against up to four tumor-associated antigens for hematologic malignancies and solid tumors. Fate will advance the different candidates through preclinical studies to the point of the filing of an Investigational New Drug Application with the U.S. Food and Drug Administration. When that time comes, Janssen will have the right to exercise its option for an exclusive license for the development and commercialization of collaboration candidates targeting the tumor-associated antigens.

Fates iPSC platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses, according to the company. The companys approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass-produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment, the company said.

Under terms of the agreement, Fate will receive $50 million in upfront cash, as well as a $50 million equity investment by Janssen. Janssen will also cover the funding costs of the R&D of the collaboration candidates. Once Janssen takes over the program, Fate will then be eligible to receive payments of up to $1.8 billion upon the achievement of development and regulatory milestones and up to $1.2 billion upon the achievement of commercial milestones. Fate will also be eligible to receive double-digit royalties on worldwide commercial sales of products targeting the antigens. Additionally, Fate has the right to co-commercialize the candidates should they be approved and share equally in profits and losses, the company said in its announcement.

Scott Wolchko, president and chief executive officer of Fate Therapeutics, touted the partnership with Janssen. He said the collaboration combines Janssens deep domain expertise in oncology, along with their proprietary technologies for targeting and binding certain tumors with Fates iPSC product platform to develop novel off-the-shelf CAR NK and T-cell cancer immunotherapies.

The collaboration strengthens our financial and operating position through a focused effort of developing cell-based cancer immunotherapies utilizing Janssens proprietary antigen-binding domains while enabling us to continue to exploit our deep pipeline of wholly-owned product candidates and further develop our off-the-shelf, iPSC-derived cell-based immunotherapies, Wolchko said in a statement.

Go here to see the original:
Fate Therapeutics Strikes Multi-Billion Dollar Cell Therapy Deal with Janssen - BioSpace

Beam Therapeutics Licenses SIRION Biotech’s LentiBOOST Technology for its CAR-T pipeline – Business Wire

MARTINSRIED, Germany--(BUSINESS WIRE)--SIRION Biotech GmbH announced today that Beam Therapeutics licensed rights to use SIRION Biotechs LentiBOOST for use in their CAR-T cell products.

CAR-T cell therapy represents a promising and future-defining shift in cancer treatment. Beam Therapeutics is developing a new generation of CAR-T product candidates using its proprietary base editing technology.

Under the terms of this agreement, SIRION agreed to provide Beam with non-exclusive access to its proprietary lentiviral transduction enhancer LentiBOOST for clinical development and commercialization of Beams portfolio of CAR-T programs. SIRION will be entitled to undisclosed upfront and milestone payments and is eligible to receive royalties on future product net sales plus license fees tied to commercial success.

Dr. Christian Thirion, CEO and founder of SIRION Biotech GmbH explains: LentiBOOST was engineered to improve lentiviral transduction of difficult cell types like T-cells and hematopoietic stem cells. This technology enables robust upscaling of the T-cell production process, and helps to reduce manufacturing costs by lowering the amount of lentiviral vectors needed for production of the cell product while at the same time improving clinical efficacy by increasing vector copy numbers (VCN) per cell. We are delighted that the LentiBOOST technology may help Beam further enhance the clinical success of its CAR-T pipeline.

LentiBOOST is used in an increasing number of clinical trials in the US and in Europe and the technology is more and more considered as a gold standard in manufacturing of cell products. Our non-exclusive licensing strategy makes our technology available to a wide range of companies and research hospitals to boost the efficiency of their various clinical programs, says SVP of Business Development & Licensing, Dr. Sabine Ott.

About SIRION Biotech GmbH

SIRION Biotech was founded in 2005 to lead the next generation of viral vector technologies for gene and cell therapy as well as vaccine development. Now SIRION offers one of the worlds most comprehensive viral vector technology platforms based on lenti-, adeno-, and adeno-associated viruses which expedites gene therapy research and advances drug development. SIRION is becoming a partner of choice in this growing sector. LentiBOOST has been used in a number of clinical trials from early stage clinical Phase 1/2 through late stage clinical Phase 3 trials and demonstrated clinical success in improving transduction of the therapeutic vector.

Continue reading here:
Beam Therapeutics Licenses SIRION Biotech's LentiBOOST Technology for its CAR-T pipeline - Business Wire

COVID-19 Impact on Stem Cell Therapy Identify Which Types of Companies Could Potentially Benefit or Loose out From the Impact of COVID-19 – Science…

Complete study of the global Stem Cell Therapy market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Stem Cell Therapy industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Stem Cell Therapy production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

Key companies operating in the global Stem Cell Therapy market include _, Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix)

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1636806/global-stem-cell-therapy-market

Segmental Analysis

The report has classified the global Stem Cell Therapy industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Stem Cell Therapy manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Stem Cell Therapy industry.

Global Stem Cell Therapy Market Segment By Type:

Autologous, Allogeneic

Global Stem Cell Therapy Market Segment By Application:

, Musculoskeletal Disorder, Wounds & Injuries, Cornea, Cardiovascular Diseases, Others

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Stem Cell Therapy industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Stem Cell Therapy market include _, Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix)

Key questions answered in the report:

Enquire Customization in The Report: https://www.qyresearch.com/customize-request/form/1636806/global-stem-cell-therapy-market

TOC

1 Market Overview of Stem Cell Therapy1.1 Stem Cell Therapy Market Overview1.1.1 Stem Cell Therapy Product Scope1.1.2 Market Status and Outlook1.2 Global Stem Cell Therapy Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Stem Cell Therapy Market Size by Region (2015-2026)1.4 Global Stem Cell Therapy Historic Market Size by Region (2015-2020)1.5 Global Stem Cell Therapy Market Size Forecast by Region (2021-2026)1.6 Key Regions Stem Cell Therapy Market Size YoY Growth (2015-2026)1.6.1 North America Stem Cell Therapy Market Size YoY Growth (2015-2026)1.6.2 Europe Stem Cell Therapy Market Size YoY Growth (2015-2026)1.6.3 China Stem Cell Therapy Market Size YoY Growth (2015-2026)1.6.4 Rest of Asia Pacific Stem Cell Therapy Market Size YoY Growth (2015-2026)1.6.5 Latin America Stem Cell Therapy Market Size YoY Growth (2015-2026)1.6.6 Middle East & Africa Stem Cell Therapy Market Size YoY Growth (2015-2026)1.7 Coronavirus Disease 2019 (Covid-19): Stem Cell Therapy Industry Impact1.7.1 How the Covid-19 is Affecting the Stem Cell Therapy Industry1.7.1.1 Stem Cell Therapy Business Impact Assessment Covid-191.7.1.2 Supply Chain Challenges1.7.1.3 COVID-19s Impact On Crude Oil and Refined Products1.7.2 Market Trends and Stem Cell Therapy Potential Opportunities in the COVID-19 Landscape1.7.3 Measures / Proposal against Covid-191.7.3.1 Government Measures to Combat Covid-19 Impact1.7.3.2 Proposal for Stem Cell Therapy Players to Combat Covid-19 Impact 2 Stem Cell Therapy Market Overview by Type2.1 Global Stem Cell Therapy Market Size by Type: 2015 VS 2020 VS 20262.2 Global Stem Cell Therapy Historic Market Size by Type (2015-2020)2.3 Global Stem Cell Therapy Forecasted Market Size by Type (2021-2026)2.4 Autologous2.5 Allogeneic 3 Stem Cell Therapy Market Overview by Type3.1 Global Stem Cell Therapy Market Size by Application: 2015 VS 2020 VS 20263.2 Global Stem Cell Therapy Historic Market Size by Application (2015-2020)3.3 Global Stem Cell Therapy Forecasted Market Size by Application (2021-2026)3.4 Musculoskeletal Disorder3.5 Wounds & Injuries3.6 Cornea3.7 Cardiovascular Diseases3.8 Others 4 Global Stem Cell Therapy Competition Analysis by Players4.1 Global Stem Cell Therapy Market Size (Million US$) by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Stem Cell Therapy as of 2019)4.3 Date of Key Manufacturers Enter into Stem Cell Therapy Market4.4 Global Top Players Stem Cell Therapy Headquarters and Area Served4.5 Key Players Stem Cell Therapy Product Solution and Service4.6 Competitive Status4.6.1 Stem Cell Therapy Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 Osiris Therapeutics5.1.1 Osiris Therapeutics Profile5.1.2 Osiris Therapeutics Main Business and Companys Total Revenue5.1.3 Osiris Therapeutics Products, Services and Solutions5.1.4 Osiris Therapeutics Revenue (US$ Million) (2015-2020)5.1.5 Osiris Therapeutics Recent Developments5.2 NuVasive5.2.1 NuVasive Profile5.2.2 NuVasive Main Business and Companys Total Revenue5.2.3 NuVasive Products, Services and Solutions5.2.4 NuVasive Revenue (US$ Million) (2015-2020)5.2.5 NuVasive Recent Developments5.3 Chiesi Pharmaceuticals5.5.1 Chiesi Pharmaceuticals Profile5.3.2 Chiesi Pharmaceuticals Main Business and Companys Total Revenue5.3.3 Chiesi Pharmaceuticals Products, Services and Solutions5.3.4 Chiesi Pharmaceuticals Revenue (US$ Million) (2015-2020)5.3.5 JCR Pharmaceutical Recent Developments5.4 JCR Pharmaceutical5.4.1 JCR Pharmaceutical Profile5.4.2 JCR Pharmaceutical Main Business and Companys Total Revenue5.4.3 JCR Pharmaceutical Products, Services and Solutions5.4.4 JCR Pharmaceutical Revenue (US$ Million) (2015-2020)5.4.5 JCR Pharmaceutical Recent Developments5.5 Pharmicell5.5.1 Pharmicell Profile5.5.2 Pharmicell Main Business and Companys Total Revenue5.5.3 Pharmicell Products, Services and Solutions5.5.4 Pharmicell Revenue (US$ Million) (2015-2020)5.5.5 Pharmicell Recent Developments5.6 Medi-post5.6.1 Medi-post Profile5.6.2 Medi-post Main Business and Companys Total Revenue5.6.3 Medi-post Products, Services and Solutions5.6.4 Medi-post Revenue (US$ Million) (2015-2020)5.6.5 Medi-post Recent Developments5.7 Anterogen5.7.1 Anterogen Profile5.7.2 Anterogen Main Business and Companys Total Revenue5.7.3 Anterogen Products, Services and Solutions5.7.4 Anterogen Revenue (US$ Million) (2015-2020)5.7.5 Anterogen Recent Developments5.8 Molmed5.8.1 Molmed Profile5.8.2 Molmed Main Business and Companys Total Revenue5.8.3 Molmed Products, Services and Solutions5.8.4 Molmed Revenue (US$ Million) (2015-2020)5.8.5 Molmed Recent Developments5.9 Takeda (TiGenix)5.9.1 Takeda (TiGenix) Profile5.9.2 Takeda (TiGenix) Main Business and Companys Total Revenue5.9.3 Takeda (TiGenix) Products, Services and Solutions5.9.4 Takeda (TiGenix) Revenue (US$ Million) (2015-2020)5.9.5 Takeda (TiGenix) Recent Developments 6 North America Stem Cell Therapy by Players and by Application6.1 North America Stem Cell Therapy Market Size and Market Share by Players (2015-2020)6.2 North America Stem Cell Therapy Market Size by Application (2015-2020) 7 Europe Stem Cell Therapy by Players and by Application7.1 Europe Stem Cell Therapy Market Size and Market Share by Players (2015-2020)7.2 Europe Stem Cell Therapy Market Size by Application (2015-2020) 8 China Stem Cell Therapy by Players and by Application8.1 China Stem Cell Therapy Market Size and Market Share by Players (2015-2020)8.2 China Stem Cell Therapy Market Size by Application (2015-2020) 9 Rest of Asia Pacific Stem Cell Therapy by Players and by Application9.1 Rest of Asia Pacific Stem Cell Therapy Market Size and Market Share by Players (2015-2020)9.2 Rest of Asia Pacific Stem Cell Therapy Market Size by Application (2015-2020) 10 Latin America Stem Cell Therapy by Players and by Application10.1 Latin America Stem Cell Therapy Market Size and Market Share by Players (2015-2020)10.2 Latin America Stem Cell Therapy Market Size by Application (2015-2020) 11 Middle East & Africa Stem Cell Therapy by Players and by Application11.1 Middle East & Africa Stem Cell Therapy Market Size and Market Share by Players (2015-2020)11.2 Middle East & Africa Stem Cell Therapy Market Size by Application (2015-2020) 12 Stem Cell Therapy Market Dynamics12.1 Industry Trends12.2 Market Drivers12.3 Market Challenges12.4 Porters Five Forces Analysis 13 Research Finding /Conclusion 14 Methodology and Data Source14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Disclaimer14.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Read the original post:
COVID-19 Impact on Stem Cell Therapy Identify Which Types of Companies Could Potentially Benefit or Loose out From the Impact of COVID-19 - Science...

Nurses life-saving stem cell transplant leaves her with an addiction to Monster Munch just like her don – The Sun

A NURSEs life-saving stem cell transplant caused her to inherit her donors addiction for pickled onion flavour Monster Munch.

Claire Stewart, 49, had never tasted the snack before the treatment but as she recovered she developed cravings for it.

6

6

She started sending bemused husband David out to buy as many bags as he could.

She said: He thought it might be a passing urge like you get when youre pregnant, but those crisps became my favourite food.

Id never eaten them before. I preferred chocolate!

The mystery was solved when she met donor Keely Jackson, 37, whose bone marrow was matched with hers by charity Anthony Nolan.

Claire, of Middlesbrough, who needed a transplant to treat a rare blood cancer, gave nurse Keely thank you gifts and a pack of Monster Munch.

Claire said: Keely gave me the strangest look like I was playing some trick on her.

She told me shed always been a secret pickled onion Monster Munch addict.

RAIN ON OUR PARADEEaster weekend washout to hit after Britain basks in mini heatwave

'BLAST' PANIC'Explosions' heard as cops launch dramatic 'gun and drug' raid in London

'DEVASTATED'NHS nurse, 29, dies from coronavirus as pals pay tribute to 'amazing' medic

STAY STRONGCoronavirus survivors give hope for PM promising 'if we can beat it, so can he'

DRUG RAPGang leader named 'The General' jailed despite 150-mile move to halt life of crime

DEADLiest dayUK suffers worst leap in coronavirus deaths yet with 786 recorded in 24hrs

Id seemingly inherited this peculiar obsession from someone whose DNA I now share.

Keely, from Wakefield, West Yorks, said: Ive got a Monster Munch friend for life!

Rebecca Pritchard, of Anthony Nolan, said: From time to time, recipients do report developing tastes shared with their donor.

She added: While all of our activities are restricted at this time, we can still help people like Claire, with blood cancer, by joining the Anthony Nolan register online or donating to our emergency appeal.

Anthony Nolan needs to raise an extra 10,000 every month that the coronavirus pandemic goes on to continue to fund their work. Visit http://www.anthonynolan.org/coronavirusemergencyappeal.

6

6

6

6

GOT a story? RING The Sun on 0207 782 4104 or WHATSAPP on 07423720250 or EMAIL exclusive@the-sun.co.uk

Read this article:
Nurses life-saving stem cell transplant leaves her with an addiction to Monster Munch just like her don - The Sun

Covid-19 Impact on Cell Freezing Media for Cell Therapy Market (2020-2026) – Science In Me

The report titled Global Cell Freezing Media for Cell Therapy Market is one of the most comprehensive and important additions to QY Researchs archive of market research studies. It offers detailed research and analysis of key aspects of the global Cell Freezing Media for Cell Therapy market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Cell Freezing Media for Cell Therapy market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Cell Freezing Media for Cell Therapy market is carefully analyzed and researched about by the market analysts.

Key companies operating in the global Cell Freezing Media for Cell Therapymarket include_BioLife Solutions, Thermo Fisher Scientific, Merck, GE Healthcare, Zenoaq, WAK-Chemie Medical, Biological Industries, Akron Biotechnology

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1548125/global-cell-freezing-media-for-cell-therapy-market

Segmental Analysis :

The report has classified the global Cell Freezing Media for Cell Therapy industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Cell Freezing Media for Cell Therapy manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Cell Freezing Media for Cell Therapy industry.

Global Cell Freezing Media for Cell Therapy Market Segment By Type:

With FBS, Without FBS

Global Cell Freezing Media for Cell Therapy Market Segment By Applications:

Human Embryonic Stem Cells, CAR-T Cell Therapy, Neural Stem Cell Therapy, Mesenchymal Stem Cell Therapy, Hematopoietic Stem Cell Transplantation, Other

Critical questions addressed by the Cell Freezing Media for Cell Therapy Market report

Reasons to Buy the Report

Get Full Customize report now at :https://www.qyresearch.com/customize-request/form/1548125/global-cell-freezing-media-for-cell-therapy-market

Table of Contents1 Cell Freezing Media for Cell Therapy Market Overview1.1 Cell Freezing Media for Cell Therapy Product Overview1.2 Cell Freezing Media for Cell Therapy Market Segment by Type1.2.1 With FBS1.2.2 Without FBS1.3 Global Cell Freezing Media for Cell Therapy Market Size by Type (2015-2026)1.3.1 Global Cell Freezing Media for Cell Therapy Market Size Overview by Type (2015-2026)1.3.2 Global Cell Freezing Media for Cell Therapy Historic Market Size Review by Type (2015-2020)1.3.2.1 Global Cell Freezing Media for Cell Therapy Sales Market Share Breakdown by Type (2015-2026)1.3.2.2 Global Cell Freezing Media for Cell Therapy Revenue Market Share Breakdown by Type (2015-2026)1.3.2.3 Global Cell Freezing Media for Cell Therapy Average Selling Price (ASP) by Type (2015-2026)1.3.3 Global Cell Freezing Media for Cell Therapy Market Size Forecast by Type (2021-2026)1.3.3.1 Global Cell Freezing Media for Cell Therapy Sales Market Share Breakdown by Application (2021-2026)1.3.3.2 Global Cell Freezing Media for Cell Therapy Revenue Market Share Breakdown by Application (2021-2026)1.3.3.3 Global Cell Freezing Media for Cell Therapy Average Selling Price (ASP) by Application (2021-2026)1.4 Key Regions Market Size Segment by Type (2015-2020)1.4.1 North America Cell Freezing Media for Cell Therapy Sales Breakdown by Type (2015-2026)1.4.2 Europe Cell Freezing Media for Cell Therapy Sales Breakdown by Type (2015-2026)1.4.3 Asia-Pacific Cell Freezing Media for Cell Therapy Sales Breakdown by Type (2015-2026)1.4.4 Latin America Cell Freezing Media for Cell Therapy Sales Breakdown by Type (2015-2026)1.4.5 Middle East and Africa Cell Freezing Media for Cell Therapy Sales Breakdown by Type (2015-2026) 2 Global Cell Freezing Media for Cell Therapy Market Competition by Company2.1 Global Top Players by Cell Freezing Media for Cell Therapy Sales (2015-2020)2.2 Global Top Players by Cell Freezing Media for Cell Therapy Revenue (2015-2020)2.3 Global Top Players Cell Freezing Media for Cell Therapy Average Selling Price (ASP) (2015-2020)2.4 Global Top Manufacturers Cell Freezing Media for Cell Therapy Manufacturing Base Distribution, Sales Area, Product Type2.5 Cell Freezing Media for Cell Therapy Market Competitive Situation and Trends2.5.1 Cell Freezing Media for Cell Therapy Market Concentration Rate (2015-2020)2.5.2 Global 5 and 10 Largest Manufacturers by Cell Freezing Media for Cell Therapy Sales and Revenue in 20192.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cell Freezing Media for Cell Therapy as of 2019)2.7 Date of Key Manufacturers Enter into Cell Freezing Media for Cell Therapy Market2.8 Key Manufacturers Cell Freezing Media for Cell Therapy Product Offered2.9 Mergers & Acquisitions, Expansion 3 Global Cell Freezing Media for Cell Therapy Status and Outlook by Region (2015-2026)3.1 Global Cell Freezing Media for Cell Therapy Market Size and CAGR by Region: 2015 VS 2020 VS 20263.2 Global Cell Freezing Media for Cell Therapy Market Size Market Share by Region (2015-2020)3.2.1 Global Cell Freezing Media for Cell Therapy Sales Market Share by Region (2015-2020)3.2.2 Global Cell Freezing Media for Cell Therapy Revenue Market Share by Region (2015-2020)3.2.3 Global Cell Freezing Media for Cell Therapy Sales, Revenue, Price and Gross Margin (2015-2020)3.3 Global Cell Freezing Media for Cell Therapy Market Size Market Share by Region (2021-2026)3.3.1 Global Cell Freezing Media for Cell Therapy Sales Market Share by Region (2021-2026)3.3.2 Global Cell Freezing Media for Cell Therapy Revenue Market Share by Region (2021-2026)3.3.3 Global Cell Freezing Media for Cell Therapy Sales, Revenue, Price and Gross Margin (2021-2026)3.4 North America Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)3.4.1 North America Cell Freezing Media for Cell Therapy Revenue YoY Growth (2015-2026)3.4.2 North America Cell Freezing Media for Cell Therapy Sales YoY Growth (2015-2026)3.5 Asia-Pacific Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)3.5.1 Asia-Pacific Cell Freezing Media for Cell Therapy Revenue YoY Growth (2015-2026)3.5.2 Asia-Pacific Cell Freezing Media for Cell Therapy Sales YoY Growth (2015-2026)3.6 Europe Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)3.6.1 Europe Cell Freezing Media for Cell Therapy Revenue YoY Growth (2015-2026)3.6.2 Europe Cell Freezing Media for Cell Therapy Sales YoY Growth (2015-2026)3.7 Latin America Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)3.7.1 Latin America Cell Freezing Media for Cell Therapy Revenue YoY Growth (2015-2026)3.7.2 Latin America Cell Freezing Media for Cell Therapy Sales YoY Growth (2015-2026)3.8 Middle East and Africa Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)3.8.1 Middle East and Africa Cell Freezing Media for Cell Therapy Revenue YoY Growth (2015-2026)3.8.2 Middle East and Africa Cell Freezing Media for Cell Therapy Sales YoY Growth (2015-2026) 4 Global Cell Freezing Media for Cell Therapy by Application4.1 Cell Freezing Media for Cell Therapy Segment by Application4.1.1 Human Embryonic Stem Cells4.1.2 CAR-T Cell Therapy4.1.3 Neural Stem Cell Therapy4.1.4 Mesenchymal Stem Cell Therapy4.1.5 Hematopoietic Stem Cell Transplantation4.1.6 Other4.2 Global Cell Freezing Media for Cell Therapy Sales by Application: 2015 VS 2020 VS 20264.3 Global Cell Freezing Media for Cell Therapy Historic Sales by Application (2015-2020)4.4 Global Cell Freezing Media for Cell Therapy Forecasted Sales by Application (2021-2026)4.5 Key Regions Cell Freezing Media for Cell Therapy Market Size by Application4.5.1 North America Cell Freezing Media for Cell Therapy by Application4.5.2 Europe Cell Freezing Media for Cell Therapy by Application4.5.3 Asia-Pacific Cell Freezing Media for Cell Therapy by Application4.5.4 Latin America Cell Freezing Media for Cell Therapy by Application4.5.5 Middle East and Africa Cell Freezing Media for Cell Therapy by Application 5 North America Cell Freezing Media for Cell Therapy Market Size by Country (2015-2026)5.1 North America Market Size Market Share by Country (2015-2020)5.1.1 North America Cell Freezing Media for Cell Therapy Sales Market Share by Country (2015-2020)5.1.2 North America Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2015-2020)5.2 North America Market Size Market Share by Country (2021-2026)5.2.1 North America Cell Freezing Media for Cell Therapy Sales Market Share by Country (2021-2026)5.2.2 North America Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2021-2026)5.3 North America Market Size YoY Growth by Country5.3.1 U.S. Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)5.3.2 Canada Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026) 6 Europe Cell Freezing Media for Cell Therapy Market Size by Country (2015-2026)6.1 Europe Market Size Market Share by Country (2015-2020)6.1.1 Europe Cell Freezing Media for Cell Therapy Sales Market Share by Country (2015-2020)6.1.2 Europe Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2015-2020)6.2 Europe Market Size Market Share by Country (2021-2026)6.2.1 Europe Cell Freezing Media for Cell Therapy Sales Market Share by Country (2021-2026)6.2.2 Europe Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2021-2026)6.3 Europe Market Size YoY Growth by Country6.3.1 Germany Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)6.3.2 France Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)6.3.3 U.K. Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)6.3.4 Italy Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)6.3.5 Russia Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026) 7 Asia-Pacific Cell Freezing Media for Cell Therapy Market Size by Country (2015-2026)7.1 Asia-Pacific Market Size Market Share by Country (2015-2020)7.1.1 Asia-Pacific Cell Freezing Media for Cell Therapy Sales Market Share by Country (2015-2020)7.1.2 Asia-Pacific Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2015-2020)7.2 Asia-Pacific Market Size Market Share by Country (2021-2026)7.2.1 Asia-Pacific Cell Freezing Media for Cell Therapy Sales Market Share by Country (2021-2026)7.2.2 Asia-Pacific Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2021-2026)7.3 Asia-Pacific Market Size YoY Growth by Country7.3.1 China Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.2 Japan Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.3 South Korea Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.4 India Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.5 Australia Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.6 Taiwan Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.7 Indonesia Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.8 Thailand Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.9 Malaysia Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.10 Philippines Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)7.3.11 Vietnam Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026) 8 Latin America Cell Freezing Media for Cell Therapy Market Size by Country (2015-2026)8.1 Latin America Market Size Market Share by Country (2015-2020)8.1.1 Latin America Cell Freezing Media for Cell Therapy Sales Market Share by Country (2015-2020)8.1.2 Latin America Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2015-2020)8.2 Latin America Market Size Market Share by Country (2021-2026)8.2.1 Latin America Cell Freezing Media for Cell Therapy Sales Market Share by Country (2021-2026)8.2.2 Latin America Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2021-2026)8.3 Latin America Market Size YoY Growth by Country8.3.1 Mexico Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)8.3.2 Brazil Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)8.3.3 Argentina Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026) 9 Middle East and Africa Cell Freezing Media for Cell Therapy Market Size by Country (2015-2026)9.1 Middle East and Africa Market Size Market Share by Country (2015-2020)9.1.1 Middle East and Africa Cell Freezing Media for Cell Therapy Sales Market Share by Country (2015-2020)9.1.2 Middle East and Africa Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2015-2020)9.2 Middle East and Africa Market Size Market Share by Country (2021-2026)9.2.1 Middle East and Africa Cell Freezing Media for Cell Therapy Sales Market Share by Country (2021-2026)9.2.2 Middle East and Africa Cell Freezing Media for Cell Therapy Revenue Market Share by Country (2021-2026)9.3 Middle East and Africa Market Size YoY Growth by Country9.3.1 Turkey Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)9.3.2 Saudi Arabia Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026)9.3.3 U.A.E Cell Freezing Media for Cell Therapy Market Size YoY Growth (2015-2026) 10 Company Profiles and Key Figures in Cell Freezing Media for Cell Therapy Business10.1 BioLife Solutions10.1.1 BioLife Solutions Corporation Information10.1.2 BioLife Solutions Description, Business Overview and Total Revenue10.1.3 BioLife Solutions Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.1.4 BioLife Solutions Cell Freezing Media for Cell Therapy Products Offered10.1.5 BioLife Solutions Recent Development10.2 Thermo Fisher Scientific10.2.1 Thermo Fisher Scientific Corporation Information10.2.2 Thermo Fisher Scientific Description, Business Overview and Total Revenue10.2.3 Thermo Fisher Scientific Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.2.5 Thermo Fisher Scientific Recent Development10.3 Merck10.3.1 Merck Corporation Information10.3.2 Merck Description, Business Overview and Total Revenue10.3.3 Merck Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.3.4 Merck Cell Freezing Media for Cell Therapy Products Offered10.3.5 Merck Recent Development10.4 GE Healthcare10.4.1 GE Healthcare Corporation Information10.4.2 GE Healthcare Description, Business Overview and Total Revenue10.4.3 GE Healthcare Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.4.4 GE Healthcare Cell Freezing Media for Cell Therapy Products Offered10.4.5 GE Healthcare Recent Development10.5 Zenoaq10.5.1 Zenoaq Corporation Information10.5.2 Zenoaq Description, Business Overview and Total Revenue10.5.3 Zenoaq Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.5.4 Zenoaq Cell Freezing Media for Cell Therapy Products Offered10.5.5 Zenoaq Recent Development10.6 WAK-Chemie Medical10.6.1 WAK-Chemie Medical Corporation Information10.6.2 WAK-Chemie Medical Description, Business Overview and Total Revenue10.6.3 WAK-Chemie Medical Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.6.4 WAK-Chemie Medical Cell Freezing Media for Cell Therapy Products Offered10.6.5 WAK-Chemie Medical Recent Development10.7 Biological Industries10.7.1 Biological Industries Corporation Information10.7.2 Biological Industries Description, Business Overview and Total Revenue10.7.3 Biological Industries Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.7.4 Biological Industries Cell Freezing Media for Cell Therapy Products Offered10.7.5 Biological Industries Recent Development10.8 Akron Biotechnology10.8.1 Akron Biotechnology Corporation Information10.8.2 Akron Biotechnology Description, Business Overview and Total Revenue10.8.3 Akron Biotechnology Cell Freezing Media for Cell Therapy Sales, Revenue and Gross Margin (2015-2020)10.8.4 Akron Biotechnology Cell Freezing Media for Cell Therapy Products Offered10.8.5 Akron Biotechnology Recent Development 11 Cell Freezing Media for Cell Therapy Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis11.1 Cell Freezing Media for Cell Therapy Key Raw Materials11.1.1 Key Raw Materials11.1.2 Key Raw Materials Price11.1.3 Raw Materials Key Suppliers11.2 Manufacturing Cost Structure11.2.1 Raw Materials11.2.2 Labor Cost11.2.3 Manufacturing Expenses11.3 Cell Freezing Media for Cell Therapy Industrial Chain Analysis11.4 Market Opportunities, Challenges, Risks and Influences Factors Analysis11.4.1 Market Opportunities and Drivers11.4.2 Market Challenges11.4.3 Market Risks11.4.4 Porters Five Forces Analysis 12 Market Strategy Analysis, Distributors12.1 Sales Channel12.2 Distributors12.3 Downstream Customers 13 Research Findings and Conclusion 14 Appendix14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Author Details14.4 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Go here to read the rest:
Covid-19 Impact on Cell Freezing Media for Cell Therapy Market (2020-2026) - Science In Me

CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19) – GlobeNewswire

NEW YORK and AUSTIN, Texas, April 07, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics (Cytovia), an emerging biopharmaceutical company developing Natural Killer (NK) immunotherapies for cancer and infectious diseases, announced today that it is expanding its programs to help urgently address the current SAR CoV2 (COVID-19) crisis.

Natural Killer cells are a first line of defense not only against tumor cells but also against severe acute infectious diseases. Using a bi-functional approach has the potential to minimize virus escape from the immune response thereby inhibiting the intensification of the inflammation leading to Acute Respiratory Syndrome (ARS). The activation of NK cells through the NKp46 receptor aims to destroy the virus-infected cells while the other arm can either block the entry of the virus into epithelial cells or neutralize circulating viruses.

Dr Daniel Teper, co-founder, Chairman and CEO of Cytovia said: Our goal is to bring the best candidate to clinical trials by the end of the year 2020 and make it available to patients in 2021. As we become more prepared for potential next waves of the pandemic, physicians will need therapeutic options to strengthen the immune response and prevent rapid worsening of the disease. We expect that our novel approach might also be applied in the future to other severe acute infectious diseases, an area that still has significant unmet medical needs. Partnering with Macromoltek will fast-track this process.

Dr Monica Berrondo, co-founder and CEO of Macromoltek added: Our computational approach to antibody design allows to fast track the development of optimal therapeutic candidates in weeks rather than months. In the fight against SARS CoV2, time is of the essence. We are delighted to be part of a multi-disciplinary team passionate about winning the race against the virus with novel therapeutic solutions.

Cytovia will lead a highly coordinated team of scientific collaborators in order to achieve aggressive timelines for its COVID-19 therapeutic program. Cytovia will leverage its own proprietary bi-functional technology, developed by co-founder Dr Kadouche, NK activating antibodies licensed last month from Yissum, the technology transfer company of the Hebrew University of Jerusalem, and novel antibodies neutralizing or blocking SARS CoV2, designed by Macromoltek, a computational antibody discovery company. The selected bi-functional antibodies will further benefit from the Fast to Clinic approach implemented by STC Biologics, a Boston, MA based antibody development and manufacturing company.

About Cytovia TherapeuticsCytovia aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer and severe acute infectious diseases. Cytovia focuses on Natural Killer (NK) cell biology and applies precision medicine tools to develop the right therapy for the right patient at the right stage of the disease. Cytovia has secured access to multiple advanced technologies, including an induced pluripotent stem cell (iPSC) platform for NK cell therapy, gene editing of Chimeric Antigen Receptors (CAR) to enhance targeting of NK cells, and NK engager multi-functional antibodies. Cytovia partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF) and the Hebrew University of Jerusalem. Learn more at http://www.cytoviatx.com.

About MacromoltekMacromoltek, a computationalde novodrug design company, rapidly producesaccurate and credible antibody designs. They have built a proprietary platform that enables design against difficult targets inaccessible by traditional methods. A Y Combinator cohort company, they are already designing antibodies for several large biopharmas and smaller biotechs. https://www.macromoltek.com

Media and Investor Contacts

Cytovia TherapeuticsSophie Badr(Media)sophiebadre21@gmail.com929.317.1565

Anna Baran Djokovic (Investors)Anna@cytoviatx.com

MacromoltekLisa Hendricksonlhendrickson@sparkcity.co917.912.9424

See the original post:
CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19) - GlobeNewswire

Coronavirus Update: Cell Therapy Reportedly Appears Promising To Beat COVID-19 – International Business Times

The scientists who developed Dolly the sheep in 1996 is, currently, developing a new therapy to treat the deadly coronavirus infection using immune cells from young and healthy volunteers.

Using Your Bodys Natural Defenses against the Virus

Such an immunity-building cell transfusion has already been used to treat cancer. The researchers believe that it will be effective against the COVID-19 as well.

One of the key challenges of fighting viral infection is to develop something that is going to attack the infected cells and not the normal cells. So the solution that we came up with was to look at the body's natural defenses to viral infection. In patients who have successfully fought a viral infection, they have expanded their own immune system and that persists after that to stop them becoming infected again," the Mirror quoted Dr. Brian Kelly, the studys senior strategic medical adviser.

According to the researchers, their treatment sees donor T-cells differ from normal immune cells as they do not identify invaders in the body based on an alien protrusion on the cells surfaces but detects the unusual metabolism of the viruses.

When the donor cells detect a virus, it starts to destroy alongside giving signals to the rest of the immune system that an alien intrusion has occurred and that it needs to be eradicated. Such an approach might be effective even when the virus is mutated or returned to a body.

Experimental Stem cell therapy by Celularity

Derived from human placentas, this new stem cell therapy will undergo early testing in COVID-19 patients. Although it hasnt yet been used on any patientwith the coronavirus symptoms, it has caught the attention of U.S. President Trumps personal lawyer Rudy Giuliani, who had tweeted that it had real potential.

There is no proven treatment yet for COVID-19 and health experts worldwide have been carrying out several experimental approaches including the old malarial drug, anti-HIV drug, and the Japanese flu drug.

Celilarity has announced its early-stage trial for COVID-19 treatment known as Cynk-001 and has described the development as the first FDA-approved COVID-19 cell therapy. It is important to note that the agency has only approved the treatment to be used in a clinical trial and not to be widely prescribed to patients.

The objective here is preventative. If the timing of giving this can prevent those patients who have early disease from progressing to the more serious, life-threatening form, it could be a very, very useful tool, The New York Times quoted Dr. Robert Hariri, Celularitys founder and chief executive.

Researchers are racing to develop treatments for the coronavirus as hospitals battle its spread Photo: AFP / STR

See the original post here:
Coronavirus Update: Cell Therapy Reportedly Appears Promising To Beat COVID-19 - International Business Times

panCELLa receives research and development support for cell therapy – Yahoo Finance

TORONTO , April 7, 2020 /CNW/ - panCELLa is pleased to announce that it will receive advisory services and up to $400,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to help further research and development of its technology platforms for cell therapy.

panCELLa Inc (CNW Group/panCELLa Inc.)

Support from NRC IRAP will go toward the research and development of a two-step safety switch known as panKiller. While panCELLa's safety switch, known as FailSafeTM, is specifically designed to eliminate only "rogue" or deregulated therapeutic cells, the panKiller system further enhances this platform and provides a means to remove a graft entirely once it has fulfilled its therapeutic purpose. When the therapeutic cells are no longer required, and to avoid serious adverse events, for further safety measures they would be eliminated using panKiller. The panKiller strategy is an effective solution that addresses serious limitations of current cell therapies which involve removal of these therapeutic cells through irradiation. panKiller will enable more prolonged, effective treatment in vivo; and will destroy the therapeutic cells at the appropriate time without the use of radiation to prevent the possibility of a malignancy.

About panCELLa

Founded in 2015, panCELLa is a privately-held early-stage biotechnology firm based on the innovative technology developed in Dr. Andras Nagy's lab at the Sinai Health System (SHS). panCELLa has created platforms that allow for the development of safe, universal, cost-effective, "off-the-shelf" cell lines. panCELLa's mandate is to accelerate cell-based therapies to a broad range of diseases by providing safe therapeutic cell products. panCELLa has secured partnerships with several biotechnology partners to enhance its patent position and provide expanded access to its exclusive FailSafeTM and Stealth CellsTM and its in-licensed SAFE harbor technology. panCELLa aims to develop therapeutic products in the immunology, mesenchymal stem cell and pancreatic islet space and to partner with other companies to develop novel products in other areas of regenerative medicine. panCELLa continues its internal R&D efforts to develop additional novel uses of its platform technologies in areas such as bio-production, cancer vaccination and tolerization. To learn more about panCELLa's FailSafeTM and induced Allogeneic Cell Tolerance, please visit https://pancella.com

SOURCE panCELLa Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/April2020/07/c5756.html

See the original post:
panCELLa receives research and development support for cell therapy - Yahoo Finance

Relief Therapeutics (RLF:SIX) Drug Aviptadil Enters FDA Trial at University of Miami, to Treat COVID-19-induced Respiratory Distress – Yahoo Finance

Aviptadil targets the cytokine storm that causes fatal Respiratory Distress in COVID-19

RELIEF THERAPEUTICS Holding AG (SIX:RLF) "Relief" announces that its drug Aviptadil has now entered FDA clinical trials at the University of Miami Miller School of Medicine for the treatment of Acute Respiratory Distress Syndrome (ARDS) in COVID-19. The trial will enroll patients who are already on mechanical ventilation in the hopes that Aviptadil can decrease mortality in this condition and help to improve the ability of the patients lung to transfer oxygen to the body.

The trial is being led by Reliefs US partner, NeuroRx, Inc., Headquartered in Radnor, PA under FDA Investigational New Drug clearance, as part of the FDAs Corona Treatment Acceleration Program (CTAP). Details are posted on clinicaltrials.gov NCT04311697. The principal investigator for the University of Miami study site is Dr. Dushyantha Jayaweera, professor of medicine. The Co-Principal Investigators are Dr. Daniel H. Kett, professor of medicine, and Dr. Daniel Dante Yeh, associate professor of surgery at the University of Miami Miller School of Medicine. The team will also collaborate with colleagues at the UM Interdisciplinary Stem Cell Institute.

"We are fortunate to have widespread support and collaboration across our institution," said Dr. Jayaweera. "As we follow rigorous scientific standards, we are cautiously optimistic that the early observations of VIP use in patients with sepsis-related ARDS will carry over to todays crisis."

Death in COVID-19-infected patients is caused by a "cytokine storm" in the lungs, in which the virus triggers inflammatory molecules called "cytokines," which cause the air sacs (alveolae) of the lungs to fill with water and become impermeable to oxygen, even in the setting of mechanical ventilation. VIP is a naturally synthesized peptide which is 40% concentrated in the lungs and which has been shown to have a potent anti-cytokine activity in numerous animal models of respiratory distress, acute lung injury, and inflammation. It has a 20-year history of safe use in human beings in multiple human trials for sarcoidosis, pulmonary fibrosis, and pulmonary hypertension, and is marketed in Europe as a local injection to treat erectile dysfunction.

Relief Therapeutics holds FDA and EU orphan drug designations for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief also holds a US patent1 for Aviptadil and proprietary manufacturing processes for its synthesis.

"In a previous trial of VIP for ARDS in patients with sepsis, 7 of 8 patients on mechanical ventilation showed substantial improvement and 6 ultimately left the hospital alive," said Prof. Jonathan Javitt, MD, MPH, the CEO of NeuroRx, Inc.. "Patients on ventilators for COVID-19 have only a 50% chance of survival. If the early results can be replicated in ARDS caused by COVID-19, this treatment could have a major impact both on COVID-19 survival and on the availability of ventilators for those in desperate need."

About RELIEF THERAPEUTICS Holding AG

The Relief group of companies focus primarily on clinical-stage projects based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rational. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications.

About RLF-100

RLF-100 (Aviptadil) is a patented formulation of Vasoactive Intestinal Polypeptide (VIP) that was originally developed and is currently marketed in Europe for the treatment of erectile dysfunction. VIP is known to be highly concentrated in the lung and to inhibit a variety of inflammatory cytokines. Aviptadil was awarded Orphan Drug Designation in 2001 by the US FDA for treatment of Acute Respiratory Distress Syndrome and in 2005 for treatment of Pulmonary Arterial Hypertension. Aviptadil was awarded Orphan Drug Designation by the European Medicines Agency in 2006 for the treatment of Acute Lung Injury and in 2007 for the treatment of Sarcoidosis. Both the US FDA and the EMEA have granted Investigational New Drug licenses for human trials of Aviptadil.

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF.

Story continues

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG and/or NeuroRx, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward looking statements contained herein as a result of new information, future events or otherwise.

1 US 8,178,489 Formulation for Aviptadil

View source version on businesswire.com: https://www.businesswire.com/news/home/20200406005881/en/

Contacts

Yves Sagotcontact@relieftherapeutics.com

Read the original here:
Relief Therapeutics (RLF:SIX) Drug Aviptadil Enters FDA Trial at University of Miami, to Treat COVID-19-induced Respiratory Distress - Yahoo Finance

Stempeutics partners with Global Consortium of cell therapy companies – Express Healthcare

Seeking European Commission Funding to Fight Against Corona

Stempeutics Research, a group company of Manipal Education and Medical Group (MEMG), recently announced that it has partnered with Global Consortium of cell therapy companies seeking European Commission Funding to Fight Against Corona! (FAC!). Under this partnership, Stempeutics will export its stem cell product Stempeucel (subject to regulatory approvals) for treating critically ill COVID-19 patients with lung disease. First the product will be clinically tested and upon successful outcomes, it intends to export the product on a regular basis. In this connection it is signing up an alliance with Educell, Slovenia.

Currently, no specific drugs or vaccines are available to cure the patients with COVID-19 infection. Mortality in COVID-19 infected patients with the inflammatory lung condition ARDS (Acute Respiratory Distress Syndrome)is reported to approach 50 per cent, and is associated with older age, co-morbidities such as diabetes, cardiovascular disease, COPD (chronic obstructive pulmonary disease), higher disease severity, and elevated markers of inflammation. Current therapeutic interventions (with the exception of ventilators / respirators which are in very short supply) do not appear to be improving in-hospital survival. Hence, there is a large unmet need for a safe and effective treatment for COVID-19 infected patients, especially in severe cases. A promising new therapy for the ARDS, the terminal stage of COVID-19, using MSCs can quickly (2-4 days) reduce inflammation of the lung tissue, and allow patients to more quickly come off of the ventilatory support and hopefully fully recover with less significant lung damage.

Stempeucel is an allogeneic, off the shelf, pooled mesenchymal stromal cells having anti- inflammatory and immune-modulatory properties which prevents the over activation of the immune system. Stempeucel product exhibits a wide range of potent therapeutic properties. The product exhibits potent immunomodulatory and anti-inflammatory properties which could help in reducing the inflammation caused due to the cytokine storm elicited by the bodys immune cells in response to SARS-CoV-2 (COVID-19) related infection in the lungs. Also, the growth factor, Angiopoietin-1 (Ang-1) is effective in reducing alveolar epithelium permeability in the lung. Hence it is envisaged, Stempeucel will reduce the fatal symptoms of COVID 19 induced pneumonia and its progression to ARDS.

Commenting on this initiative, Dr Miomir Knezevic, Leader, Global Consortium and Founder, Educell said, We are happy to partner with Stempeutics since its product Stempeucel is already designated as an ATMP [1] in Europe and also Stempeucel technology has been patented in many countries in Europe. Stempeutics manufacturing process is scalable and the product is affordable which are key to meet the demands of COVID-19 patients.

BN Manohar, CEO, Stempeutics said, From the clinical data using Stempeucel in different clinical trials in other indications it may be postulated that Stempeucel has the potential capability for treating COVID-19 infection. Together with the safety profile observed from DCGI approved clinical trials involving more than 350 patients injected with Stempeucel by different routes of injection, this therapy may help in mitigating the lung tissue damaging effects of COVID-19 infection.

Dr Stephen Minger, Scientific Advisor, Global Consortium and ex Global Director of R&D, Cell Technologies GE Healthcare added, The most severely affected CV-2 infected patients will often go on to develop ARDS which necessitates assisted ventilation to preserve breathing and lung function. Moreover, many ARDS patients will also experience an acute but severe life-threatening inflammatory response (cytokine storm) which can result in long-term damage to lung tissue and lung function. Treating ARDS patients with allogeneic expanded bone marrow derived MSCs could alleviate and ameliorate lung inflammation and compromised lung function and significantly reduce the time required for patients to be ventilated.

Dr Raviraja NS, Sr Director, Business Development and Innovation, Stempeutics, said, Given the severe shortage of ventilators in the world, and the high mortality rate of patients who develop ARDS (approx. 50 per cent), the clinical use of MSCs in COVID-19 ADRS patients could drastically impact on the healthcare burden currently occurring due to very large patient numbers, limited equipment and overworked medical personnel.

Reference:

[1] ATMP is Advanced Therapy Medicinal Product regulated by EU Act December 7, 2007.

Continued here:
Stempeutics partners with Global Consortium of cell therapy companies - Express Healthcare